NasdaqGS - Delayed Quote USD

Novavax, Inc. (NVAX)

3.9500 -0.2000 (-4.82%)
At close: 4:00 PM EDT
3.9698 +0.02 (+0.50%)
After hours: 4:40 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
556,382.0000
556,382.0000
1,598,951.0000
197,581.0000
22,388.0000
Cost of Revenue
343,768.0000
343,768.0000
902,639.0000
--
--
Gross Profit
212,614.0000
212,614.0000
696,312.0000
197,581.0000
22,388.0000
Operating Expense
779,125.0000
779,125.0000
1,341,048.0000
1,884,157.0000
439,107.0000
Operating Income
-566,511.0000
-566,511.0000
-644,736.0000
-1,686,576.0000
-416,719.0000
Net Non Operating Interest Income Expense
-14,416.0000
-14,416.0000
-19,880.0000
-21,127.0000
-15,145.0000
Other Income Expense
37,896.0000
37,896.0000
10,969.0000
-6,833.0000
13,605.0000
Pretax Income
-543,031.0000
-543,031.0000
-653,647.0000
-1,714,536.0000
-418,259.0000
Tax Provision
2,031.0000
2,031.0000
4,292.0000
29,215.0000
--
Net Income Common Stockholders
-545,062.0000
-545,062.0000
-657,939.0000
-1,743,751.0000
-418,259.0000
Diluted NI Available to Com Stockholders
-545,062.0000
-545,062.0000
-657,939.0000
-1,743,751.0000
-418,259.0000
Basic EPS
-5.41
--
-8.42
-23.44
-7.27
Diluted EPS
-5.41
--
-8.42
-23.44
-7.27
Basic Average Shares
100,768.0000
--
78,183.0000
74,400.0000
57,554.0000
Diluted Average Shares
100,768.0000
--
78,183.0000
74,400.0000
57,554.0000
Total Operating Income as Reported
-566,511.0000
-566,511.0000
-644,736.0000
-1,686,576.0000
-416,719.0000
Total Expenses
1,122,893.0000
1,122,893.0000
2,243,687.0000
1,884,157.0000
439,107.0000
Net Income from Continuing & Discontinued Operation
-545,062.0000
-545,062.0000
-657,939.0000
-1,743,751.0000
-418,259.0000
Normalized Income
-545,062.0000
-545,062.0000
-657,939.0000
-1,743,751.0000
-418,259.0000
Interest Expense
14,416.0000
14,416.0000
19,880.0000
21,127.0000
15,145.0000
Net Interest Income
-14,416.0000
-14,416.0000
-19,880.0000
-21,127.0000
-15,145.0000
EBIT
-528,615.0000
-528,615.0000
-633,767.0000
-1,693,409.0000
-403,114.0000
EBITDA
-487,390.0000
-487,390.0000
-604,713.0000
-1,680,748.0000
-398,229.0000
Reconciled Cost of Revenue
343,768.0000
343,768.0000
902,639.0000
--
--
Reconciled Depreciation
41,225.0000
41,225.0000
29,054.0000
12,661.0000
4,885.0000
Net Income from Continuing Operation Net Minority Interest
-545,062.0000
-545,062.0000
-657,939.0000
-1,743,751.0000
-418,259.0000
Total Unusual Items Excluding Goodwill
--
--
--
1,364.0000
1,014.0000
Total Unusual Items
--
--
--
1,364.0000
1,014.0000
Normalized EBITDA
-487,390.0000
-487,390.0000
-604,713.0000
-1,680,748.0000
-398,229.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
--
12/31/2020 - 12/5/1995

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRNA Moderna, Inc.
106.18
-2.45%
 
IOVA Iovance Biotherapeutics, Inc.
11.54
-1.45%
 
INO Inovio Pharmaceuticals, Inc.
10.13
-0.34%
 
VXRT Vaxart, Inc.
0.6584
-7.23%
 
BNTX BioNTech SE
86.71
-1.57%
 
OCGN Ocugen, Inc.
1.1800
0.00%
 
IBRX ImmunityBio, Inc.
5.11
+6.02%
 
BLUE bluebird bio, Inc.
0.9125
-1.13%
 
SAVA Cassava Sciences, Inc.
21.73
+4.77%
 
VKTX Viking Therapeutics, Inc.
68.86
+5.82%